It’s All About Abecma As 2seventy Sells Off Pipeline To Regeneron In Restructuring

The cell therapy biotech will reduce its headcount from 280 to 65, with most of them – including two execs – going to Regeneron, which is paying just $5m up front to become a cell therapy player.

• Source: Shutterstock

2seventy Bio, Inc. is taking a small initial payment to sell off its cell therapy pipeline to Regeneron Pharmaceuticals, Inc. amid a restructuring that is designed to allow the company to focus on its one marketed product, the Bristol Myers Squibb Company-partnered multiple myeloma CAR-T therapy Abecma (idecabtagene vicleucel). Meanwhile, the deal gives Regeneron an opportunity to become a cell therapy player on top of its rapidly expanding presence in immuno-oncology.

The transaction announced on 30 January sharpens 2seventy’s focus on Abecma just ahead of a US Food and Drug Administration decision that could move the BCMA-targeting treatment into earlier lines...

Key Takeaways
  • After lower-than-expected sales of Abecma prompted a restructuring, 2seventy will receive just $5m up front as it sells its R&D pipeline to Regeneron, which will hire...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

Lilly To Diversify Pain Pipeline With SiteOne Acquisition

 
• By 

Deal snapshot: With several internal non-opioid pain candidates in Phase II or earlier, Lilly looks to add R&D potential in pain with $1bn buyout of SiteOne.

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By 

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

Deal Watch: QurAlis Targets Fragile-X Syndrome In Deals With Quiver, UMass

 
• By 

Plus the end of Sanofi’s six-target alliance with IGM, OmniAb’s deals with Veraxa and Angelini, alliances involving Skye/Arecor, Genprex/UTHealth Houston and more.

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.

More from Business

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: Novo Nordisk’s CEO forced out; quantifying biopharma’s contribution to the US economy; a history of MASH deals; lift for AstraZeneca’s asthma ambitions; and major Japanese firms see US revenue growth.

Sun On Leqselvi US Launch Ahead, MFN Pricing And Pipeline Changes

 

Sun readies US debut of Leqselvi for alopecia areata, while PD-L1 inhibitor Unloxcyt is in the line up once the Checkpoint Therapeutics deal is completed. Management also discusses limited clarity on President Trump’s most favored nation pricing push, pipeline tweaks and M&A outlook.

Lilly To Diversify Pain Pipeline With SiteOne Acquisition

 
• By 

Deal snapshot: With several internal non-opioid pain candidates in Phase II or earlier, Lilly looks to add R&D potential in pain with $1bn buyout of SiteOne.